Document is current
Any future updates will be listed below
-
Authors
Dopeso, Higinio http://orcid.org/0000-0003-0060-1861
Gazzo, Andrea M.
Derakhshan, Fatemeh http://orcid.org/0000-0002-1346-589X
Brown, David N.
Selenica, Pier
Jalali, Sahar
Da Cruz Paula, Arnaud http://orcid.org/0000-0001-7694-8760
Marra, Antonio http://orcid.org/0000-0002-7310-7824
da Silva, Edaise M. http://orcid.org/0000-0003-3281-7333
Basili, Thais
Gusain, Laxmi
Colon-Cartagena, Lorraine
Bhaloo, Shirin Issa
Green, Hunter http://orcid.org/0009-0002-3944-6803
Vanderbilt, Chad
Oesterreich, Steffi
Grabenstetter, Anne
Kuba, M. Gabriela
Ross, Dara
Giri, Dilip
Wen, Hannah Y.
Zhang, Hong
Brogi, Edi
Weigelt, Britta
Pareja, Fresia http://orcid.org/0000-0003-3748-8049
Reis-Filho, Jorge S.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P50 CA247749 01, P30CA008748, P50 CA247749 01)
Breast Cancer Research Foundation
- License Information
-
More Information
Article History
Received: 10 May 2023
Accepted: 14 December 2023
First Online: 12 February 2024
Competing interests
: J.S.R.-F. reports receiving personal/consultancy fees from Goldman Sachs, Bain Capital, REPARE Therapeutics, Saga Diagnostics, MultiplexDX and Paige.AI, membership of the scientific advisory boards of VolitionRx, REPARE Therapeutics and Paige.AI, membership of the Board of Directors of Grupo Oncoclinicas, and ad hoc membership of the scientific advisory boards of AstraZeneca, Merck, Daiichi Sankyo, Roche Tissue Diagnostics and Personalis, outside the scope of this study. B.W. reports research funding from Repare Therapeutics, outside the scope of the submitted work. F.P. reports consultancy fees from AstraZeneca and membership of the scientific advisory board of MultiplexDx and the diagnostic advisory board of AstraZeneca. All other authors declare no financial or non-financial competing interests.
